

Veronique Maguer-Satta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3140438/publications.pdf>

Version: 2024-02-01

70
papers

2,487
citations

186265

28
h-index

206112

48
g-index

76
all docs

76
docs citations

76
times ranked

4135
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	2.8	239
2	Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer. <i>Stem Cells</i> , 2011, 29, 389-396.	3.2	151
3	The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. <i>Nature Cancer</i> , 2020, 1, 672-680.	13.2	132
4	The effect of environmental chemicals on the tumor microenvironment. <i>Carcinogenesis</i> , 2015, 36, S160-S183.	2.8	97
5	Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGF β 2 family. <i>Experimental Cell Research</i> , 2003, 282, 110-120.	2.6	89
6	Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. <i>Oncogene</i> , 2002, 21, 2227-2235.	5.9	79
7	Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. <i>Blood</i> , 2013, 122, 3767-3777.	1.4	76
8	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. <i>Journal of the National Cancer Institute</i> , 2018, 110, 467-478.	6.3	76
9	The CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells. <i>Stem Cells</i> , 2010, 28, 1081-1088.	3.2	72
10	Cancer Stem Cells: The Emerging Challenge of Drug Targeting. <i>Current Medicinal Chemistry</i> , 2009, 16, 394-416.	2.4	64
11	The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. <i>Haematologica</i> , 2013, 98, 1510-1516.	3.5	61
12	The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. <i>Leukemia</i> , 2015, 29, 1993-2002.	7.2	56
13	BCR-ABL expression in different subpopulations of functionally characterized Ph ⁺ CD34 ⁺ cells from patients with chronic myeloid leukemia. <i>Blood</i> , 1996, 88, 1796-1804.	1.4	54
14	Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPRIb Cell Response. <i>Stem Cell Reports</i> , 2015, 4, 239-254.	4.8	54
15	Deregulation of TWIST-1 in the CD34 ⁺ compartment represents a novel prognostic factor in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 1673-1676.	1.4	51
16	During hematopoiesis, expression of FLRG, a novel activin A ligand, is regulated by TGF- β 2. <i>Experimental Hematology</i> , 2001, 29, 301-308.	0.4	47
17	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. <i>Blood</i> , 2008, 112, 3154-3163.	1.4	47
18	BCR-ABL accelerates C2-ceramide-induced apoptosis. <i>Oncogene</i> , 1998, 16, 237-248.	5.9	46

#	ARTICLE	IF	CITATIONS
19	Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 1540-1552.	7.2	46
20	Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e37-e46.	4.6	45
21	FLRG, an activin-binding protein, is a new target of TGF β 2 transcription activation through Smad proteins. <i>Oncogene</i> , 2001, 20, 5409-5419.	5.9	42
22	Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2002, 99, 4647-4649.	1.4	42
23	The critical role of the <sc>ZNF217</sc> oncogene in promoting breast cancer metastasis to the bone. <i>Journal of Pathology</i> , 2017, 242, 73-89.	4.5	42
24	Local Mitochondrial-Endolysosomal Microfusion Cleaves Voltage-Dependent Anion Channel 1 To Promote Survival in Hypoxia. <i>Molecular and Cellular Biology</i> , 2015, 35, 1491-1505.	2.3	40
25	Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling. <i>Cell Death and Differentiation</i> , 2017, 24, 155-166.	11.2	39
26	FLRG, member of the follistatin family, a new player in hematopoiesis. <i>Molecular and Cellular Endocrinology</i> , 2004, 225, 109-118.	3.2	36
27	Pancreatic Lymph Nodes are Early Targets of T Cells during Adoptive Transfer of Diabetes in NOD Mice. <i>Journal of Autoimmunity</i> , 1995, 8, 323-334.	6.5	35
28	Immature CML cells implement a BMP autocrine loop to escape TKI treatment. <i>Blood</i> , 2017, 130, 2860-2871.	1.4	35
29	The BMP pathway: A unique tool to decode the origin and progression of leukemia. <i>Experimental Hematology</i> , 2018, 61, 36-44.	0.4	33
30	Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence. <i>Stem Cell Investigation</i> , 2017, 4, 67-67.	3.0	30
31	Developmental and cancer-associated plasticity of DNA replication preferentially targets GC-poor, lowly expressed and late-replicating regions. <i>Nucleic Acids Research</i> , 2018, 46, 10157-10172.	14.5	30
32	Human placenta and fetal membranes express follistatin-related gene mRNA and protein. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 641-645.	3.3	29
33	A new signaling cascade linking BMP4, BMPRI1, β 73 and NANOG impacts on stem-like human cell properties and patient outcome. <i>Cell Death and Disease</i> , 2018, 9, 1011.	6.3	28
34	TP63 P2 promoter functional analysis identifies β -catenin as a key regulator of β 63 expression. <i>Oncogene</i> , 2011, 30, 4656-4665.	5.9	26
35	FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation. <i>Biology of the Cell</i> , 2005, 97, 577-588.	2.0	24
36	A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin. <i>Experimental Cell Research</i> , 2006, 312, 434-442.	2.6	24

#	ARTICLE	IF	CITATIONS
37	Sex differences in the GSK3 β -mediated survival of adherent leukemic progenitors. <i>Oncogene</i> , 2012, 31, 694-705.	5.9	24
38	Human immature thymocytes as target cells of the leukemogenic activity of human T-cell leukemia virus type I. <i>Blood</i> , 1995, 86, 1444-1452.	1.4	23
39	Deciphering the internal complexity of living cells with quantitative phase microscopy: a multiscale approach. <i>Journal of Biomedical Optics</i> , 2015, 20, 096005.	2.6	22
40	The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission. <i>Haematologica</i> , 2020, 106, 111-122.	3.5	22
41	Human endometrium and decidua express follistatin-related gene (FLRG) mRNA and peptide. <i>Molecular and Cellular Endocrinology</i> , 2004, 218, 129-135.	3.2	21
42	Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma. <i>European Journal of Endocrinology</i> , 2004, 151, 251-257.	3.7	20
43	Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. <i>Blood</i> , 2000, 96, 4118-4123.	1.4	18
44	Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein. <i>Gene Therapy</i> , 1998, 5, 556-562.	4.5	17
45	Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. <i>Leukemia Research</i> , 2011, 35, 38-43.	0.8	17
46	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. <i>Leukemia Research</i> , 2011, 35, 448-458.	0.8	17
47	Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. <i>Leukemia</i> , 2008, 22, 2131-2134.	7.2	16
48	Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia. <i>Biochemical Society Transactions</i> , 2020, 48, 411-418.	3.4	14
49	BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1026527.	0.7	13
50	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. <i>Frontiers in Oncology</i> , 2020, 10, 712.	2.8	13
51	Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 766275.	4.8	13
52	Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells. <i>Cell Proliferation</i> , 2019, 52, e12611.	5.3	11
53	Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins. <i>Cancers</i> , 2019, 11, 1351.	3.7	9
54	Blocking TGF- β 2 and BMP SMAD-dependent cell differentiation is a master key to expand all kinds of epithelial stem cells. <i>Stem Cell Investigation</i> , 2016, 3, 88-88.	3.0	8

#	ARTICLE	IF	CITATIONS
55	A new agarose-based microsystem to investigate cell response to prolonged confinement. Lab on A Chip, 2020, 20, 4016-4030.	6.0	8
56	CD10: A tool to crack the role of stem cells in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1264-E1264.	7.1	7
57	Altered BMP2/4 Signaling in Stem Cells and Their Niche: Different Cancers but Similar Mechanisms, the Example of Myeloid Leukemia and Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 787989.	3.7	6
58	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia. Blood Advances, 2022, 6, 3611-3624.	5.2	6
59	Ex Vivo Cytokine Expansion of Peripheral Blood Ph-Negative Cells in Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1998, 32, 151-157.	1.3	5
60	A Protocol to Quantify Mammary Early Common Progenitors from Long-Term Mammosphere Culture. Current Protocols in Stem Cell Biology, 2012, 20, Unit 1E.7.	3.0	5
61	In vitro Use of Primary Human Hematopoietic Cells as a Model to Investigate the Regulation of Erythropoiesis. Transfusion Medicine and Hemotherapy, 2004, 31, 33-40.	1.6	4
62	Enlightening intracellular complexity of living cells with quantitative phase microscopy. , 2016, , .		3
63	Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. Blood, 2000, 96, 4118-4123.	1.4	3
64	ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular Metabolism, 2021, 55, 101410.	6.5	3
65	Single-cell analysis of autophagy activity in normal and de novo transformed human mammary cells. Scientific Reports, 2020, 10, 20266.	3.3	2
66	Quantifying Epithelial Early Common Progenitors from Long-Term Primary or Cell Line Sphere Culture. Current Protocols in Stem Cell Biology, 2015, 35, 1E.7.1-1E.7.8.	3.0	1
67	BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood, 1996, 88, 1796-1804.	1.4	1
68	T3151+ tyrosine-kinase independent CML cells resistance. Oncotarget, 2017, 8, 43600-43601.	1.8	1
69	A minimal standardized human bone marrow microphysiological system to assess resident cell behavior during normal and pathological processes. Biomaterials Science, 2022, 10, 485-498.	5.4	1
70	A Potential New Mechanism for Bisphenol Molecules to Initiate Breast Cancer through Alteration of Bone Morphogenetic Protein Signaling in Stem Cells and Their Microenvironment. , 0, , .		0